Last reviewed · How we verify
Crystalloid Infusion
Crystalloid infusion replaces intravascular fluid volume and electrolytes to restore hemodynamic stability and tissue perfusion.
Crystalloid infusion replaces intravascular fluid volume and electrolytes to restore hemodynamic stability and tissue perfusion. Used for Hypovolemia and shock (hemorrhagic, septic, cardiogenic), Perioperative fluid management, Dehydration and electrolyte replacement.
At a glance
| Generic name | Crystalloid Infusion |
|---|---|
| Sponsor | University of Washington |
| Drug class | Intravenous fluid replacement therapy |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Supportive Care |
| Phase | FDA-approved |
Mechanism of action
Crystalloid solutions (typically normal saline or balanced electrolyte solutions) are administered intravenously to expand the intravascular compartment and restore circulating blood volume. These solutions contain water and electrolytes in physiologic concentrations, allowing fluid to distribute across intracellular and extracellular compartments. Crystalloid infusion is a foundational supportive therapy used to treat hypovolemia, maintain organ perfusion, and correct electrolyte abnormalities across multiple clinical settings.
Approved indications
- Hypovolemia and shock (hemorrhagic, septic, cardiogenic)
- Perioperative fluid management
- Dehydration and electrolyte replacement
- Maintenance fluid therapy in hospitalized patients
Common side effects
- Fluid overload / pulmonary edema
- Hyperchloremic acidosis
- Hyponatremia (with excessive hypotonic solutions)
- Phlebitis at infusion site
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Normal Saline Infusion After Intravenous Thrombolysis in Stroke (PHASE3)
- Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial (PHASE3)
- Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2) (PHASE1, PHASE2)
- Intravenous Lidocaine Infusion in Lumbar Fusion Surgery (NA)
- Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy (PHASE2)
- Gelaspan vs Crystalloid Therapy in Sepsis (PHASE4)
- Angiotensin II in Liver Transplantation (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Crystalloid Infusion CI brief — competitive landscape report
- Crystalloid Infusion updates RSS · CI watch RSS
- University of Washington portfolio CI